company background image
ECS

ECS Botanics HoldingsASX:ECS Stock Report

Market Cap

AU$35.4m

7D

-5.1%

1Y

12.1%

Updated

18 Oct, 2021

Data

Company Financials +
ECS fundamental analysis
Snowflake Score
Valuation1/6
Future Growth5/6
Past Performance0/6
Financial Health3/6
Dividends0/6

ECS Overview

ECS Botanics Holdings Ltd engages in the cultivation, manufacture, and sale of medicinal cannabis products.

Price History & Performance

Summary of all time highs, changes and price drops for ECS Botanics Holdings
Historical stock prices
Current Share PriceAU$0.037
52 Week HighAU$0.023
52 Week LowAU$0.078
Beta1.14
1 Month Change-13.95%
3 Month Change-9.76%
1 Year Change12.12%
3 Year Changen/a
5 Year Changen/a
Change since IPO-43.08%

Recent News & Updates

Feb 24
ECS Botanics Holdings (ASX:ECS) Is In A Good Position To Deliver On Growth Plans

ECS Botanics Holdings (ASX:ECS) Is In A Good Position To Deliver On Growth Plans

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Shareholder Returns

ECSAU PharmaceuticalsAU Market
7D-5.1%0.04%0.9%
1Y12.1%-2.4%20.2%

Return vs Industry: ECS exceeded the Australian Pharmaceuticals industry which returned -2.4% over the past year.

Return vs Market: ECS underperformed the Australian Market which returned 20.2% over the past year.

Price Volatility

Is ECS's price volatile compared to industry and market?
ECS volatility
ECS Beta1.14
Industry Beta1.3
Market Beta1

Stable Share Price: ECS is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: ECS's weekly volatility has decreased from 16% to 9% over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/an/aAlex Keachhttps://ecsbotanics.com.au

ECS Botanics Holdings Ltd engages in the cultivation, manufacture, and sale of medicinal cannabis products. It also retails hemp wellness and food products; and engages in the agriculture business. The company is based in Launceston, Australia.

ECS Botanics Holdings Fundamentals Summary

How do ECS Botanics Holdings's earnings and revenue compare to its market cap?
ECS fundamental statistics
Market CapAU$35.36m
Earnings (TTM)-AU$4.34m
Revenue (TTM)AU$1.38m

24.5x

P/S Ratio

-7.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ECS income statement (TTM)
RevenueAU$1.38m
Cost of RevenueAU$1.16m
Gross ProfitAU$210.55k
ExpensesAU$4.55m
Earnings-AU$4.34m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.0048
Gross Margin15.31%
Net Profit Margin-315.30%
Debt/Equity Ratio0.008%

How did ECS perform over the long term?

See historical performance and comparison

Valuation

Is ECS Botanics Holdings undervalued compared to its fair value and its price relative to the market?

1.96x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ECS's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate ECS's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: ECS is unprofitable, so we can't compare its PE Ratio to the Oceanic Pharmaceuticals industry average.

PE vs Market: ECS is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ECS's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ECS is good value based on its PB Ratio (2x) compared to the AU Pharmaceuticals industry average (3.3x).


Future Growth

How is ECS Botanics Holdings forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

103.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ECS is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).

Earnings vs Market: ECS is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: ECS's is expected to become profitable in the next 3 years.

Revenue vs Market: ECS's revenue (62.9% per year) is forecast to grow faster than the Australian market (5.5% per year).

High Growth Revenue: ECS's revenue (62.9% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ECS's Return on Equity is forecast to be high in 3 years time


Past Performance

How has ECS Botanics Holdings performed over the past 5 years?

5.1%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: ECS is currently unprofitable.

Growing Profit Margin: ECS is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if ECS's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare ECS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ECS is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (17.4%).


Return on Equity

High ROE: ECS has a negative Return on Equity (-25.37%), as it is currently unprofitable.


Financial Health

How is ECS Botanics Holdings's financial position?


Financial Position Analysis

Short Term Liabilities: ECS's short term assets (A$8.0M) exceed its short term liabilities (A$1.4M).

Long Term Liabilities: ECS's short term assets (A$8.0M) exceed its long term liabilities (A$18.2K).


Debt to Equity History and Analysis

Debt Level: ECS's debt to equity ratio (0.01%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if ECS's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ECS has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: ECS has less than a year of cash runway if free cash flow continues to reduce at historical rates of 55.2% each year


Dividend

What is ECS Botanics Holdings's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ECS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ECS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ECS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ECS's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ECS's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.7yrs

Average management tenure


CEO

Alex Keach

2.25yrs

Tenure

AU$195,000

Compensation

Mr. Alexander Keach, also known as Alex, is the Founder at ECS Botanics Holdings Ltd. He is also the Managing Director at ECS Botanics Holdings Ltd since July 11, 2019. He was employed in many roles at Bel...


CEO Compensation Analysis

Compensation vs Market: Alex's total compensation ($USD144.73K) is below average for companies of similar size in the Australian market ($USD302.72K).

Compensation vs Earnings: Alex's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: ECS's management team is not considered experienced ( 0.7 years average tenure), which suggests a new team.


Board Members

Experienced Board: ECS's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: ECS insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 55.1%.


Top Shareholders

Company Information

ECS Botanics Holdings Ltd's employee growth, exchange listings and data sources


Key Information

  • Name: ECS Botanics Holdings Ltd
  • Ticker: ECS
  • Exchange: ASX
  • Founded: NaN
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: AU$35.362m
  • Shares outstanding: 906.73m
  • Website: https://ecsbotanics.com.au

Location

  • ECS Botanics Holdings Ltd
  • 94 Green Rises Road
  • Cressy
  • Launceston
  • Tasmania
  • 7302
  • Australia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/18 07:03
End of Day Share Price2021/10/18 00:00
Earnings2021/06/30
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.